Structure-based drug design strategies in medicinal chemistry.

A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the development of high quality drug candidates. Structure-based drug design (SBDD) methods are becoming increasingly powerful, versatile and more widely used. This review summarizes current developments in structure-based virtual screening and receptor-based pharmacophores, highlighting achievements as well as challenges, along with the value of structure-based lead optimization, with emphasis on recent examples of successful applications for the identification of novel active compounds.

[1]  Piotr Setny,et al.  Search for Novel Aminoglycosides by Combining Fragment-Based Virtual Screening and 3D-QSAR Scoring , 2009, J. Chem. Inf. Model..

[2]  Gerhard Klebe,et al.  Use of 3D QSAR Models for Database Screening: A Feasibility Study , 2008, J. Chem. Inf. Model..

[3]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Oliva,et al.  Virtual screening and its integration with modern drug design technologies. , 2008, Current medicinal chemistry.

[5]  Thomas Lengauer,et al.  Structure Based Drug Design , 2005 .

[6]  Magdalena Bacilieri,et al.  The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist. , 2006, Bioorganic & medicinal chemistry.

[7]  T L Blundell,et al.  Protein structure--based drug design. , 1994, Annual review of biophysics and biomolecular structure.

[8]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[9]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[10]  A. Andricopulo,et al.  Fragment-Based QSAR and Molecular Modeling Studies on a Series of Discodermolide Analogs as Microtubule-Stabilizing Anticancer Agents , 2009 .

[11]  A. Bisi,et al.  Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. , 2008, Journal of medicinal chemistry.

[12]  Tad Hurst,et al.  Flexible 3D searching: The directed tweak technique , 1994, J. Chem. Inf. Comput. Sci..

[13]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[14]  Olivier Taboureau,et al.  Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands , 2009, J. Chem. Inf. Model..

[15]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[16]  E. Leahy,et al.  Optimization of a screening lead for factor VIIa/TF. , 2001, Bioorganic & medicinal chemistry letters.

[17]  Y. Kurogi,et al.  Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.

[18]  O Pelkonen,et al.  New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) analysis , 2007, British journal of pharmacology.

[19]  Jürg Zimmermann,et al.  Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives. , 1997 .

[20]  Ruben Abagyan,et al.  Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[22]  Chong Hak Chae,et al.  Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[23]  Robin Taylor,et al.  SuperStar: a knowledge-based approach for identifying interaction sites in proteins. , 1999, Journal of molecular biology.

[24]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[25]  M. Dawson,et al.  3D-QSAR and QSSR studies of 3,8-diazabicyclo[4.2.0]octane derivatives as neuronal nicotinic acetylcholine receptors by comparative molecular field analysis (CoMFA). , 2009, Bioorganic & medicinal chemistry letters.

[26]  Thomas Lengauer,et al.  Flexible docking under pharmacophore type constraints , 2002, J. Comput. Aided Mol. Des..

[27]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[28]  Alexander Golbraikh,et al.  Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. , 2004, Journal of medicinal chemistry.

[29]  P. Potter,et al.  Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. , 2009, Bioorganic & medicinal chemistry.

[30]  E. Benfenati,et al.  A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. , 2008, Journal of molecular graphics & modelling.

[31]  Gerhard Klebe,et al.  Recent developments in structure-based drug design , 2000, Journal of Molecular Medicine.

[32]  D. Abraham,et al.  Hydrophobicity: is LogP(o/w) more than the sum of its parts? , 2000, European journal of medicinal chemistry.

[33]  Adriano D. Andricopulo,et al.  Structure-Based Approach for the Study of Estrogen Receptor Binding Affinity and Subtype Selectivity , 2008, J. Chem. Inf. Model..

[34]  David J. Livingstone,et al.  The Characterization of Chemical Structures Using Molecular Properties. A Survey , 2000, J. Chem. Inf. Comput. Sci..

[35]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[36]  Christine Humblet,et al.  Lead optimization via high-throughput molecular docking. , 2007, Current opinion in drug discovery & development.

[37]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[38]  Claudio N. Cavasotto,et al.  Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.

[39]  M. Grütter,et al.  The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. , 1991, Journal of structural biology.

[40]  Tracey Clark,et al.  Synthesis and structure based optimization of novel Akt inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[41]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[42]  Thierry Langer,et al.  Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.

[43]  Rieko Arimoto,et al.  Computational models for predicting interactions with cytochrome p450 enzyme. , 2006, Current topics in medicinal chemistry.

[44]  Ashutosh Kumar,et al.  Knowledge Based Identification of Potent Antitubercular Compounds Using Structure Based Virtual Screening and Structure Interaction Fingerprints , 2009, J. Chem. Inf. Model..

[45]  B D Silverman,et al.  Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. , 1996, Journal of medicinal chemistry.

[46]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[47]  B. Shoichet,et al.  Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[48]  Paul D Lyne,et al.  Structure-based virtual screening: an overview. , 2002, Drug discovery today.

[49]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[50]  Nico P E Vermeulen,et al.  Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. , 2003, Journal of medicinal chemistry.

[51]  Paolo Bonvini,et al.  Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.

[52]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[53]  Anna Marabotti,et al.  Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water. , 2002, Journal of medicinal chemistry.

[54]  Hans-Joachim Böhm,et al.  LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads , 1992, J. Comput. Aided Mol. Des..

[55]  Christian Lemmen,et al.  Coupling structure-based design with combinatorial chemistry: application of active site derived pharmacophores with informative library design. , 2002, Journal of molecular graphics & modelling.

[56]  Gerhard Klebe,et al.  Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. , 2002, Journal of medicinal chemistry.

[57]  N. P. Todorov,et al.  Receptor flexibility in de novo ligand design and docking. , 2005, Journal of medicinal chemistry.

[58]  Thomas Lengauer,et al.  FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.

[59]  Vincenza Andrisano,et al.  Development and characterization of an immobilized enzyme reactor based on glyceraldehyde-3-phosphate dehydrogenase for on-line enzymatic studies. , 2003, Journal of chromatography. A.

[60]  Claudio N. Cavasotto,et al.  In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. , 2006, Bioorganic & medicinal chemistry letters.

[61]  Glen E. Kellogg,et al.  Hydrophobicity: is LogPo/w more than the sum of its parts? , 2000 .

[62]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[63]  Nigel J Waters,et al.  Quantitative structure activity relationships in drug metabolism. , 2006, Current topics in medicinal chemistry.

[64]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[65]  M. Vrtacnik,et al.  HQSAR and CoMFA approaches in predicting reactivity of halogenated compounds with hydroxyl radicals. , 2003, Chemosphere.

[66]  J. Tuszynski,et al.  Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. , 2009, Journal of molecular graphics & modelling.

[67]  Pietro Cozzini,et al.  Getting it right: modeling of pH, solvent and "nearly" everything else in virtual screening of biological targets. , 2004, Journal of molecular graphics & modelling.

[68]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[69]  Elizabeth Igne Ferreira,et al.  Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents , 2008 .

[70]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[71]  J. Briggs,et al.  Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. , 2006, Journal of medicinal chemistry.

[72]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[73]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[74]  J. Wood,et al.  CGP 38 560: Orally Active, Low‐Molecular‐Weight Renin Inhibitor with High Potency and Specificity , 1989, Journal of cardiovascular pharmacology.

[75]  Cristina Tintori,et al.  Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery , 2008, J. Chem. Inf. Model..

[76]  Ingo Muegge.  Synergies of virtual screening approaches. , 2008, Mini reviews in medicinal chemistry.

[77]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[78]  John J Irwin,et al.  Here Be Dragons: Docking and Screening in an Uncharted Region of Chemical Space , 2005, Journal of biomolecular screening.

[79]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[80]  Maria Paola Costi,et al.  Structure-Based Optimization of a Non-β-lactam Lead Results in Inhibitors That Do Not Up-Regulate β-Lactamase Expression in Cell Culture , 2005 .

[81]  Taraneh Mirzadegan,et al.  Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. , 2008, Journal of medicinal chemistry.

[82]  I. Polikarpov,et al.  3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. , 2007, Journal of molecular graphics & modelling.

[83]  J. Sutherland,et al.  A comparison of methods for modeling quantitative structure-activity relationships. , 2004, Journal of medicinal chemistry.

[84]  Glaucius Oliva,et al.  Structural Basis for Selective Inhibition of Trypanosomatid Glyceraldehyde-3-Phosphate Dehydrogenase: Molecular Docking and 3D QSAR Studies , 2008, J. Chem. Inf. Model..

[85]  L. Hardy,et al.  The impact of structure-guided drug design on clinical agents , 2003 .

[86]  Alexander D. MacKerell,et al.  Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. , 2004, Journal of medicinal chemistry.

[87]  Holger Gohlke,et al.  Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.

[88]  Gerhard Klebe,et al.  Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II. , 2001, Angewandte Chemie.

[89]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[90]  C. Hansch,et al.  Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. , 2001, Chemical reviews.

[91]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[92]  D. Joseph-McCarthy,et al.  Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors. , 2008, Journal of medicinal chemistry.

[93]  J. Irwin,et al.  Lead discovery using molecular docking. , 2002, Current opinion in chemical biology.

[94]  I. Kuntz,et al.  Protein docking and complementarity. , 1991, Journal of molecular biology.

[95]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[96]  Jing Chen,et al.  Pocket v.2: Further Developments on Receptor-Based Pharmacophore Modeling , 2006, J. Chem. Inf. Model..

[97]  David A. Winkler,et al.  The role of quantitative structure-activity relationships (QSAR) in biomolecular discovery , 2002, Briefings Bioinform..

[98]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[99]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[100]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[101]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[102]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[103]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[104]  Marta Murcia,et al.  Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. , 2004, Journal of medicinal chemistry.

[105]  H. Brunner,et al.  Aliskiren: the first renin inhibitor for clinical treatment , 2008, Nature Reviews Drug Discovery.

[106]  Glaucius Oliva,et al.  Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies. , 2009, Journal of molecular graphics & modelling.

[107]  Peter Gedeck,et al.  Exploiting QSAR models in lead optimization. , 2008, Current opinion in drug discovery & development.

[108]  Maria Paola Costi,et al.  Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. , 2005, Journal of the American Chemical Society.

[109]  G. Klebe,et al.  Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. , 2002, Angewandte Chemie.

[110]  Stefano Alcaro,et al.  GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition , 2006, Bioinform..

[111]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[112]  Glaucius Oliva,et al.  Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[113]  Pietro Cozzini,et al.  Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes. , 2004, Journal of medicinal chemistry.

[114]  G. Oliva,et al.  Development and characterization of an immobilized enzyme reactor (IMER) based on human glyceraldehyde-3-phosphate dehydrogenase for on-line enzymatic studies. , 2006, Journal of chromatography. A.

[115]  Peter Kuhn,et al.  The genesis of high-throughput structure-based drug discovery using protein crystallography. , 2002, Current opinion in chemical biology.

[116]  Adriano D Andricopulo,et al.  Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. , 2007, Journal of molecular graphics & modelling.

[117]  Thierry Langer,et al.  Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..

[118]  H. Gmuender,et al.  Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors. , 1993, Pharmacology & therapeutics.

[119]  A. Doweyko,et al.  The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules. , 1988, Journal of medicinal chemistry.

[120]  Jeffrey P. Jones,et al.  Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. , 2008, Bioorganic & medicinal chemistry.

[121]  Thomas Hermann,et al.  Drugs targeting the ribosome. , 2005, Current opinion in structural biology.

[122]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[123]  G Klebe,et al.  On the prediction of binding properties of drug molecules by comparative molecular field analysis. , 1993, Journal of medicinal chemistry.

[124]  T. Poulos,et al.  Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. , 2009, Journal of medicinal chemistry.

[125]  C. Nickel,et al.  Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. , 2006, Bioorganic & medicinal chemistry letters.

[126]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[127]  Allan M. Ferguson,et al.  EVA: A new theoretically based molecular descriptor for use in QSAR/QSPR analysis , 1997, J. Comput. Aided Mol. Des..

[128]  G. Klebe,et al.  DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.

[129]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[130]  A. Andricopulo,et al.  Structure-activity relationships for the design of small-molecule inhibitors. , 2005, Mini reviews in medicinal chemistry.

[131]  T Langer,et al.  Lead optimization Pharmacophore definition and 3 D searches , 2005 .

[132]  Alexander Tropsha,et al.  Application of validated QSAR models of D1 dopaminergic antagonists for database mining. , 2005, Journal of medicinal chemistry.

[133]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[134]  Brian K Shoichet,et al.  Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. , 2002, Structure.

[135]  Ingo Muegge,et al.  3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method , 2001 .

[136]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[137]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[138]  Leonard Buckbinder,et al.  Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. , 2008, Bioorganic & medicinal chemistry letters.

[139]  Adriano D. Andricopulo,et al.  Fragment-based QSAR: perspectives in drug design , 2009, Molecular Diversity.

[140]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[141]  Gerhard Klebe,et al.  Predicting binding modes, binding affinities and ‘hot spots’ for protein-ligand complexes using a knowledge-based scoring function , 2000 .